医学
肾细胞癌
免疫疗法
肾癌
肿瘤科
无容量
癌症
内科学
重症监护医学
作者
Soki Kashima,David A. Braun
标识
DOI:10.1016/j.ucl.2023.01.012
摘要
The management of advanced renal cell carcinoma has advanced tremendously over the past decade, but most patients still do not receive durable clinical benefit from current therapies. Renal cellcarcinoma is an immunogenic tumor, historically with conventional cytokine therapies, such as interleukin-2 and interferon-α, and contemporarily with the introduction of immune checkpoint inhibitors. Now the central therapeutic strategy in renal cell carcinoma is combination therapies including immunecheckpoint inhibitors. In this Review, we look back on the historical changes in systemic therapy for advanced renal cell carcinoma, and focus on the latest developments and prospects in this field.
科研通智能强力驱动
Strongly Powered by AbleSci AI